The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
On Information and Sufficiency
Kullback, S., & Leibler, R. A. (1951) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177729694 · Cited by 20,193
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Anderson, N. L., & Anderson, N. G. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r200007-mcp200 · Cited by 4,414
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
Melo, S. A., Luecke, L. B., Kahlert, C., Fernandez, A. F., Gammon, S. T., Kaye, J., LeBleu, V. S., Mittendorf, E. A., Weitz, J., Rahbari, N., et al. (2015) · Nature · doi:10.1038/nature14581 · Cited by 2,880
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Kamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00141-0 · Cited by 2,212
Reactivity of a monoclonal antibody with human ovarian carcinoma.
Bast, R. C., Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B., & Knapp, R. C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110380 · Cited by 1,661
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Perez, E. A., Olson, J. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510764 · Cited by 1,388
Zhang, Z., Bast, R. C., Yu, Y., Li, J., Sokoll, L. J., Rai, A. J., Rosenzweig, J. M., Cameron, B., Wang, Y. Y., Meng, X.-Y., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0746 · Cited by 934
Mining the plasma proteome for cancer biomarkers
Hanash, S. M., Pitteri, S. J., & Faca, V. M. (2008) · Nature · doi:10.1038/nature06916 · Cited by 891
Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes
Zethelius, B., Berglund, L., Sundström, J., Ingelsson, E., Basu, S., Larsson, A., Venge, P., & Ärnlöv, J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707064 · Cited by 889
Reproducibility: Standardize antibodies used in research
Bradbury, A., & Plückthun, A. (2015) · Nature · doi:10.1038/518027a · Cited by 647
Rai, A. J., Gelfand, C. A., Haywood, B. C., Warunek, D. J., Yi, J., Schuchard, M. D., Mehigh, R. J., Cockrill, S. L., Scott, G. B. I., Tammen, H., et al. (2005) · PROTEOMICS · doi:10.1002/pmic.200401245 · Cited by 545
ELISA in the multiplex era: Potentials and pitfalls
Tighe, P. J., Ryder, R. R., Todd, I., & Fairclough, L. C. (2015) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201400130 · Cited by 464
Olsson, E., Winter, C., George, A., Chen, Y., Howlin, J., Tang, M. E., Dahlgren, M., Schulz, R., Grabau, D., van Westen, D., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404913 · Cited by 453
Protein microarrays: Meeting analytical challenges for clinical applications
Liotta, L. A., Espina, V., Mehta, A. I., Calvert, V., Rosenblatt, K., Geho, D., Munson, P. J., Young, L., Wulfkuhle, J., & Petricoin, E. F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00086-2 · Cited by 446
Dynamic range of mass accuracy in LTQ orbitrap hybrid mass spectrometer
Makarov, A., Denisov, E., Lange, O., & Horning, S. (2006) · Journal of the American Society for Mass Spectrometry · doi:10.1016/j.jasms.2006.03.006 · Cited by 431
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges
Füzéry, A. K., Levin, J., Chan, M. M., & Chan, D. W. (2013) · Clinical Proteomics · doi:10.1186/1559-0275-10-13 · Cited by 428
Grönberg, H., Adolfsson, J., Aly, M., Nordström, T., Wiklund, P., Brandberg, Y., Thompson, J., Wiklund, F., Lindberg, J., Clements, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00361-7 · Cited by 407
A list of candidate cancer biomarkers for targeted proteomics.
Polanski, M., & Anderson, N. L. (2007) · PubMed Central · Cited by 350
A multi-dimensional model of clinical utility
Smart, A. (2006) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzl034 · Cited by 265
Serum Biomarker Panels for the Detection of Pancreatic Cancer
Brand, R. E., Nolen, B. M., Zeh, H. J., Allen, P. J., Eloubeidi, M. A., Goldberg, M., Elton, E., Arnoletti, J. P., Christein, J. D., Vickers, S. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0248 · Cited by 239
Parker, C. E., & Borchers, C. H. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.03.006 · Cited by 238
Abbatiello, S. E., Schilling, B., Mani, D. R., Zimmerman, L. J., Hall, S. C., MacLean, B., Albertolle, M., Allen, S., Burgess, M., Cusack, M. P., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.047050 · Cited by 215
Antibody-based proteomics: fast-tracking molecular diagnostics in oncology
Brennan, D. J., O'Connor, D. P., Rexhepaj, E., Ponten, F., & Gallagher, W. M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2902 · Cited by 208
Zhang, Z., & Chan, D. W. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0580 · Cited by 207
Cancer biomarkers: a systems approach
Hartwell, L., Mankoff, D., Paulovich, A., Ramsey, S., & Swisher, E. (2006) · Nature Biotechnology · doi:10.1038/nbt0806-905 · Cited by 201
Menon, U., Ryan, A., Kalsi, J., Gentry-Maharaj, A., Dawnay, A., Habib, M., Apostolidou, S., Singh, N., Benjamin, E., Burnell, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4945 · Cited by 196
Increased Selectivity, Analytical Precision, and Throughput in Targeted Proteomics
Kiyonami, R., Schoen, A., Prakash, A., Peterman, S., Zabrouskov, V., Picotti, P., Aebersold, R., Huhmer, A., & Domon, B. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.002931 · Cited by 177
Biomarkers in prostate cancer: what's new?
Sartori, D. A., & Chan, D. W. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000065 · Cited by 172
Applications of antibody array platforms
Haab, B. B. (2006) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2006.06.013 · Cited by 170
Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses
Coleman, R. L., Herzog, T. J., Chan, D. W., Munroe, D. G., Pappas, T. C., Smith, A., Zhang, Z., & Wolf, J. K. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2016.03.003 · Cited by 151
The Long Journey of Cancer Biomarkers from the Bench to the Clinic
Pavlou, M. P., Diamandis, E. P., & Blasutig, I. M. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.184614 · Cited by 150
Design of high-density antibody microarrays for disease proteomics: Key technological issues
Borrebaeck, C. A. K., & Wingren, C. (2009) · Journal of Proteomics · doi:10.1016/j.jprot.2009.01.027 · Cited by 141
Self-citationFrantzi, M., Bhat, A. V., & Latosińska, A. (2014) · Clinical and Translational Medicine · doi:10.1186/2001-1326-3-7 · Cited by 141
Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay
Bristow, R. E., Smith, A., Zhang, Z., Chan, D. W., Crutcher, G., Fung, E. T., & Munroe, D. G. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.11.022 · Cited by 137
Identification of Serum Biomarker Signatures Associated with Pancreatic Cancer
Wingren, C., Gerdtsson, A. S., Segersvärd, R., Carlsson, A., Andersson, R. E., Löhr, M. J., & Borrebaeck, C. A. K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2883 · Cited by 122
Self-citationEllmark, P., Ingvarsson, J., Carlsson, A., Lundin, B. S., Wingren, C., & Borrebaeck, C. A. K. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m600170-mcp200 · Cited by 112
Self-citationSerum proteome profiling of metastatic breast cancer using recombinant antibody microarrays
Carlsson, A., Wingren, C., Ingvarsson, J., Ellmark, P., Baldertorp, B., Fernö, M., Olsson, H. L., & Borrebaeck, C. A. K. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.11.025 · Cited by 111
Self-citationProtein Microarrays for Personalized Medicine
Yu, X., Schneiderhan‐Marra, N., & Joos, T. O. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.137158 · Cited by 111
Sample size calculations for comparative studies of medical tests for detecting presence of disease
Alonzo, T. A., PEPE, M. S., & Moskowitz, C. S. (2002) · Statistics in Medicine · doi:10.1002/sim.1058 · Cited by 107
Genome Medicine: the future of medicine
Norton, M. L. (2009) · Genome Medicine · doi:10.1186/gm1 · Cited by 99
Nolen, B. M., Brand, R. E., Prosser, D., Velikokhatnaya, L., Allen, P. J., Zeh, H. J., Grizzle, W. E., Lomakin, A., & Lokshin, A. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094928 · Cited by 97
Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature
Ghatnekar, O., Andersson, R., Svensson, M., Persson, U., Ringdahl, U., Zeilon, P., & Borrebaeck, C. A. K. (2013) · International Journal of Cancer · doi:10.1002/ijc.28256 · Cited by 85
Self-citationCarlsson, A., Wingren, C., Kristensson, M., Rose, C., Fernö, M., Olsson, H. L., Jernström, H., Ek, S., Gustavsson, E., Ingvar, C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103125108 · Cited by 83
Self-citationShimizu, Y., Yasui, K., Matsueda, K., Yanagisawa, A., & Yamao, K. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03895.x · Cited by 72
The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index
Heijnsdijk, E. A. M., Denham, D., & de Koning, H. J. (2016) · Value in Health · doi:10.1016/j.jval.2015.12.002 · Cited by 56
FDA Perspective on Companion Diagnostics: An Evolving Paradigm
Mansfield, E. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1954 · Cited by 52
Razavi, M., Anderson, N. L., Yip, R., Pope, M. E., & Pearson, T. W. (2016) · Bioanalysis · doi:10.4155/bio-2016-0059 · Cited by 52
Mirus, J. E., Zhang, Y., Li, C. I., Lokshin, A. E., Prentice, R. L., Hingorani, S. R., & Lampe, P. D. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3474 · Cited by 47
Recombinant Antibodies for the Generation of Antibody Arrays
Borrebaeck, C. A. K., & Wingren, C. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-286-1_17 · Cited by 45
Self-citationOncoproteomic profiling with antibody microarrays
Alhamdani, M. S. S., Schröder, C., & Hoheisel, J. D. (2009) · Genome Medicine · doi:10.1186/gm68 · Cited by 43
Gerdtsson, A. S., Andersson, R. E., Segersvärd, R., Löhr, M. J., Borrebaeck, C. A. K., & Wingren, C. (2012) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201200051 · Cited by 36
Self-citationGerdtsson, A. S., Wingren, C., Persson, H., Delfani, P., Nordström, M., Ren, H., Wen, X., Ringdahl, U., Borrebaeck, C. A. K., & Hao, J. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.07.001 · Cited by 31
Self-citationGerdtsson, A. S., Malats, N., Säll, A., Real, F. X., Porta, M. S., Skoog, P., Persson, H., Wingren, C., & Borrebaeck, C. A. K. (2015) · International Journal of Proteomics · doi:10.1155/2015/587250 · Cited by 30
Self-citationMirus, J. E., Zhang, Y., Hollingsworth, M. A., Solan, J. L., Lampe, P. D., & Hingorani, S. R. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.036517 · Cited by 28
Leveraging Biospecimen Resources for Discovery or Validation of Markers for Early Cancer Detection
Schully, S. D., Carrick, D. M., Mechanic, L. E., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv012 · Cited by 27
Lee, M., Kim, J. H., Lee, J.-S., Yun, S. J., Kim, W., Ahn, H., & Park, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125405 · Cited by 25
Proteomics Research to Discover Markers: What Can We Learn from Netflix®?
Ransohoff, D. F. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.126698 · Cited by 25
Network views for personalized medicine
Vlahou, A. (2013) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201200121 · Cited by 15
Waldemarson, S., Kurbasic, E., Krogh, M., Cifani, P., Berggård, T., Borg, Å., & James, P. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0732-2 · Cited by 11
Cited by
Nanotechnology in cancer diagnosis: progress, challenges and opportunities
Zhang, Y., Li, M., Gao, X., Chen, Y., & Liu, T. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0833-3 · Cited by 510
Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine
Adir, O., Poley, M., Chen, G., Froim, S., Krinsky, N., Shklover, J., Shainsky‐Roitman, J., Lammers, T., & Schroeder, A. (2020) · Advanced Materials · doi:10.1002/adma.201901989 · Cited by 496
The emerging role of mass spectrometry-based proteomics in drug discovery
Meissner, F., Geddes-McAlister, J., Mann, M., & Bantscheff, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00409-3 · Cited by 341
Screen-printed electrodes: Transitioning the laboratory in-to-the field
García-Miranda Ferrari, A., Rowley-Neale, S. J., & Banks, C. E. (2021) · Talanta Open · doi:10.1016/j.talo.2021.100032 · Cited by 315
Jahani, Y., Arvelo, E. R., Yesilkoy, F., Koshelev, K., Cianciaruso, C., De Palma, M., Kivshar, Y., & Altug, H. (2021) · Nature Communications · doi:10.1038/s41467-021-23257-y · Cited by 304
Metadata
- Authors
- Borrebaeck, C. A. K.
- Venue
- Nature Reviews Cancer
- Published
- 2017-02-03
- Volume
- 17
- Issue
- 3
- Pages
- 199-204
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2583706707
- Cited by
- 435
- References
- 64
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.